In this podcast, Dr. Gary Lyman describes biosimilars for cancer treatment and why they are important. He also talks about why ASCO is releasing a statement on them today.
In this podcast, Dr. Erica Mayer reviews research highlights from the San Antonio Breast Cancer Symposium. New insights into hormone therapy, targeted therapy, joint stiffness, and fertility preservation are covered.
In this podcast, Cancer.Net Associate Editor Dr. Michael Williams describes lymphoma research advances presented at the American Society of Hematology Annual Meeting.
In this podcast, Cancer.Net Associate Editor Ezra Cohen, MD, FRCPC, discusses some of the key themes that arose at the 2017 3rd World Congress on Thyroid Cancer.
ASCO Annual Meeting 2017: Advances in Immunotherapy for Multiple Myeloma and Mesothelioma, and Targeted Therapies for Non-Small Cell Lung Cancer and HER2-Positive Breast Cancer
Oncology professionals from around the globe are in Chicago for the ASCO Annual Meeting. Today’s key research highlights include CAR T-cell therapy for multiple myeloma, immune checkpoint inhibitors for mesothelioma, and targeted therapy advances for non-small cell lung cancer and HER2-positive breast cancer.
ASCO Annual Meeting 2017: Symptom Reporting Extends Lives, Shorter Chemotherapy for Some Colon Cancer Patients, and Targeted Therapy in BRCA-Related Breast Cancer
Oncology professionals from around the globe are in Chicago for the ASCO Annual Meeting. Research released today covers how using a web-based system to report symptoms helps patients live longer, a shorter schedule of chemotherapy can be an option for certain people with colon cancer, and a targeted therapy may slow the growth of BRCA-related breast cancer.
ASCO Annual Meeting 2017: News on Breast Cancer, Prostate Cancer, TRK Fusion Protein Inhibition, Using Blood Tests to Screen for Cancer, and Genomic Testing
Oncology professionals from around the globe are in Chicago for the ASCO Annual Meeting. Research highlights from today include pregnancy after breast cancer, abiraterone for prostate cancer, a new medication that targets a rare genetic abnormality, new blood test technology for cancer screening, and genomic testing.
Identifying genetic changes has given us new insights in early detection and treatment of advanced and castration-resistant prostate cancer.
The Targeted Agent and Profiling Utilization Registry (TAPUR) study is ASCO’s first clinical trial. In this podcast, ASCO Chief Medical Officer Dr. Richard Schilsky discusses TAPUR and why it is important to patients and the medical community.
These studies from the ASCO Annual Meeting show some of the newest thoughts and latest advances in using immunotherapy and targeted therapy to treat bladder, stomach, and lung cancers.